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Diagnosing tuberculosis in hospitalized
HIV-infected individuals who cannot
produce sputum: is urine
lipoarabinomannan testing the answer?
Natasha F. Sabur1,2†, Aliasgar Esmail1†, Mantaj S. Brar3 and Keertan Dheda1,4*
Abstract
Background: Up to one third of HIV-infected individuals with suspected TB are sputum-scarce. The Alere
Determine™ TB LAM Ag lateral flow strip test can be used to diagnose TB in HIV-infected patients with advanced
immunosuppression. However, how urine LAM testing should be incorporated into testing algorithms and in the
context of specific patient sub-groups remains unclear.
Methods: This study represents a post hoc sub-group analysis of data from a randomized multi-center parent
study. The study population consisted of hospitalized HIV-infected patients with suspected TB who were
unable to produce sputum and who underwent urine LAM testing. The diagnostic utility of urine LAM for TB
in this group was compared to the performance of urine LAM in patients who did produce a sputum sample
in the parent study.
Results: There were a total of 187 and 2341 patients in the sputum-scarce and sputum-producing cohorts,
respectively. 80 of the sputum-scarce patients underwent testing with urine LAM. In comparison to those
who did produce sputum, sputum-scarce patients had a younger age, a lower Karnofsky performance score,
and a lower weight and BMI at admission. A greater proportion of sputum-scarce patients were urine LAM
positive, compared to those who were able to produce sputum (31% vs. 21%, p = 0.04). A higher proportion
of sputum-scarce patients died within 8 weeks of admission (32% vs. 24%, p = 0.013). We inferred that 19% of
HIV-infected sputum-scarce patients suspected of TB were diagnosed with tuberculosis by urine LAM testing,
with an estimated positive predictive value of 63% (95% CI 43–82%).
Conclusions: Urine LAM testing can effectively identify tuberculosis in HIV-infected patients who are at a
higher risk of mortality yet are unable to generate a sputum sample for diagnostic testing. Our findings
support the use of urine LAM testing in sputum-scarce hospitalized HIV-infected patients, and its
incorporation into diagnostic algorithms for this patient population.
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Background
Despite many recent advances in the diagnosis of tuber-
culosis (TB), it is estimated that one third of all TB cases
are missed (either not diagnosed or not reported) [1, 2].
Current diagnostic tests for pulmonary TB rely on
generation of a sputum sample. Historically, sputum mi-
croscopy, where sputum is examined under microscopy
for acid-fast bacilli, has been the first-line test for TB.
The World Health Organization (WHO) now advocates
for the Xpert MTB/RIF test, an automated real-time
polymerase chain reaction assay for detection of M. tu-
berculosis and rifampicin resistance, [3] as the initial
diagnostic test for all adults and children with suspected
TB [4]. The Xpert MTB/RIF test has demonstrated im-
proved accuracy over smear microscopy, and has re-
sulted in an improvement in time to treatment initiation
for TB patients [5, 6]. However, despite allowing for
more rapid diagnostic results as well as information on
first line drug resistance, the Xpert MTB/RIF assay also
requires the patient to generate a sputum sample of ad-
equate quality and volume for this test to yield a result.
The HIV epidemic has changed the face of tubercu-
losis, particularly in Africa, where nearly 40% of active
TB cases are co-infected with HIV [2]. In this popula-
tion, TB often does not produce cavities and sputum has
a low bacillary load [7], rendering a significant propor-
tion of patients smear-negative [8–10], and up to a third
of patients unable to produce sputum for diagnostic test-
ing [11]. Various methods of sputum acquisition includ-
ing sputum induction and bronchoscopy have been
tested in this population, but these methods are expen-
sive and require special facilities [12, 13]. Additionally,
they require significant processing time and often do not
provide same-day diagnosis, which has particular rele-
vance in high-burden settings where many patients fail
to return for results and are therefore often lost to
follow-up [14]. Moreover, in hospitalized HIV-infected
patients, post-mortem studies have illustrated a large
burden of undiagnosed TB [15], and in this popula-
tion rapid initiation of TB treatment may reduce
mortality [1, 16, 17].
Lipoarabinomannan (LAM), an immunogenic glyco-
lipid component of the bacterial cell wall excreted in the
urine, offers a unique method for detection of M. tuber-
culosis [18–20] and has been recently shown to reduce
mortality in hospitalized HIV patients when used to
guide TB treatment initiation [21]. Urine LAM testing
would likely have particular utility in HIV patients who
are unable to produce a sputum sample, as urine speci-
mens are generally easily obtained. Although the WHO
has published guidelines about the use of urine LAM,
they do not address how the test should be used in diag-
nostic algorithms when alternative tests are available (ex.
Xpert MTB/RIF, smear microscopy, culture, etc.), or
which patient sub-groups would benefit from specific
first-line testing strategies [22]. To our knowledge, the
performance of urine LAM specifically in sputum-scarce
HIV patients has not previously been evaluated. To ad-
dress this knowledge gap, we evaluated the diagnostic
utility of urine LAM testing in a cohort of hospitalized
HIV-infected patients unable to generate an adequate
sputum sample for conventional TB testing.
Methods
Study design
This study represents a post hoc sub-group analysis of
data from a pragmatic, randomized, parallel arm, multi-
center study with stratified randomization by country.
The primary analysis has already been reported [21].
The study was approved by the appropriate national
regulatory authorities and by the University of Cape
Town Human Research Ethics Committee. All patients
provided informed written consent in their first lan-
guage. This trial was registered with Clinicaltrials.gov
(https://clinicaltrials.gov/ct2/show/NCT01770730).
Patient enrollment and randomization
Patients admitted to ten urban or peri-urban hospitals in
South Africa, Tanzania, Zambia and Zimbabwe were
screened for study inclusion. A detailed description of
hospital care, HIV and TB prevalence, routine clinical
care, and the diagnostics infrastructure at each hospital
are previously reported. [21] The inclusion criteria in-
cluded: i) HIV-infected persons; ii) at least one of the
following symptoms: current fever or cough, drenching
night sweats, or self-reported loss-of-weight; iii) illness
severe enough to necessitate hospitalization; iv) age ≥
18 years; v) granting of informed consent. The exclusion
criteria included: i) patients receiving any anti-TB medi-
cation in the 60 days prior to testing, and ii) unable to
provide at least 30mls urine. Eligible patients were ran-
domized to receive standard available TB diagnostics at
each center or standard TB diagnostics plus adjunctive
LAM, using centralized computer-generated allocation
lists, stratified by country. The patients and the study
team were not masked to both allocation and test re-
sults. In addition to a urine specimen, patients were
asked to expectorate a minimum of two sputa for rou-
tine TB diagnosis. For patients unable to self-
expectorate, sputum induction was employed. Clinical
assessment by the attending physicians and chest x-ray
(CXR) facilities were available in most cases, however
additional radiology and non-sputum sampling was dif-
ferentially available in study hospitals and requesting
these investigations was at the discretion of the attend-
ing clinical team. For patients in the study arm, Alere
Determine™ TB LAM Ag lateral flow strip test testing
was performed at the bedside, according to
Sabur et al. BMC Infectious Diseases  (2017) 17:803 Page 2 of 6
manufacturer’s instructions. A grade 2 cutoff point or
higher was deemed as a positive urine LAM result. The
attending clinical team made all decisions regarding pa-
tient therapy and initiation of anti-TB treatment and the
timing thereof, including acting upon the LAM test re-
sults. The WHO guidelines for the treatment of smear-
negative tuberculosis were routinely used at study
hospitals.
Outcomes and statistical analysis
The goal of this analysis was to assess the diagnostic
utility of urine LAM for TB in HIV-infected patients ad-
mitted for suspected TB and who were unable to pro-
duce an adequate sputum sample. As no reference
standard exists for the diagnosis of TB in the absence of
a sputum sample, the findings of the LAM test were
compared to the performance in patients who did pro-
duce a sputum sample in this study. Exact binomial 95%
confidence intervals were calculated for proportions,
and differences in proportions were calculated with 95%
confidence intervals (using a normal-approximation) for
comparisons between the groups. For categorical vari-
ables, differences between groups were evaluated using
chi-square tests. For continuous variables, differences in
means were calculated and t-tests were employed to
evaluate differences in means between groups (applying
the central-limit theorem to non-normal distributions).
Results
Patients
Of the 2528 patients enrolled in the study, a total of 222
patients did not have a sputum result. 35 of these
patients generated a sputum sample but no result was
recorded; therefore, these patients were not included in
the sputum-scarce cohort. The remaining 187 patients
(7.4% of the randomized patients) were unable to
produce a sputum sample despite the availability of
sputum induction facilities at all hospital sites.
Baseline characteristics
In this sputum-scarce cohort of 187 patients, the mean
age was 36 years and 51% were female. In comparison to
those who did produce a sputum sample, there was
evidence that these patients were younger, had a lower
Karnofsky performance score, and had a lower weight
and BMI at admission (Table 1). In addition, there was
evidence of an association with being unable to produce
sputum and recruitment from Zambia, as a dispropor-
tionate number of sputum-scarce patients were recruited
from this site. There was no evidence of a difference in
baseline CD4+ count (Table 1).
Outcomes
Among the sputum-scarce cohort of 187 patients, 80 pa-
tients were assigned to the LAM study arm of the parent
study and had urine LAM testing performed. A greater
proportion of patients in this group were urine LAM
positive, compared to those who were able to produce a
sputum sample (31% vs. 21%, p = 0.04, Table 2). In
addition, a greater proportion of patients underwent
CXR (88% vs. 55%, p < 0.001) and were felt by the
treating clinician to have a CXR suggestive of tuber-
culosis, compared to those who produced sputum
(59% vs. 48%, p = 0.010). However, there was no evi-
dence that the proportion of patients who received
treatment for TB varied by the ability to produce a
sputum sample (48% vs. 49%, p = 0.68). A higher pro-
portion of those unable to produce sputum died
within 8 weeks of admission (32% vs. 24%, p = 0.013).
Due to the lack of a reference standard for the diagno-
sis of TB in patients who cannot produce sputum, we
used the diagnostic accuracy of urine LAM testing in
those able to produce sputum and applied the false-
positive rate to this cohort (using sputum culture posi-
tivity as the reference standard for the diagnosis of TB).
This assumes the specificity of the urine LAM test does
not differ among the patient populations that are able
and unable to produce sputum, as CD4+ counts did not
differ between these groups. Among those who were
able to produce sputum, were sputum culture negative,
and underwent LAM testing, 11.8% were found to have
a positive urine LAM result (100/848, 95% CI 9.6–
14.1%), which we considered the false positive rate of
the test. Among those unable to produce sputum and
who underwent a urine LAM test, 31% were found to
have a positive urine LAM test (25/80, 95% CI 21%–
Table 1 Baseline characteristics in HIV-infected persons stratified by ability to produce a sputum sample
Sputum-Scarce
N = 187
Sputum-Producing
N = 2341
p-value
Mean age in years (SD) 36.3 (9.6) 37.9 (10.5) 0.031
Sex distribution M:F (% males) 92:95 (49%) 1136:1205 (49%) 0.86
Mean CD4+ Count in cells/mm3 (SD) 178 (241) 150 (176) 0.15
Mean Karnofsky Score (SD) 50.6 (12.4) 53.4 (16.1) 0.005
Mean weight in Kg (SD) 47.8 (9.1) 53.4 (12.0) <0.001
Mean BMI (SD) 17. 2 (3.3) 19.5 (4.4) <0.001
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43%). The difference between these two proportions was
used to estimate the true positive rate of urine LAM
testing in those unable to produce a sputum sample, and
was estimated at 19% (95% CI 9.0–30%); i.e. 19% of
HIV-infected patients suspected of TB but unable to
produce a sputum specimen are diagnosed with TB with
the use of a urine LAM test. Under these assumptions,
the positive predictive value of a positive urine LAM test
in this cohort is estimated as 63% (95% CI 43–82%).
Discussion
In this study, we identified a group of hospitalized, HIV-
infected, sputum-scarce patients in whom diagnosis of
tuberculosis was particularly challenging, and in whom a
missed diagnosis could have had fatal consequences.
Compared to the larger cohort of patients with sus-
pected TB who were able to provide a sputum sample
for diagnostic testing, this group had a lower weight and
Karnofsky performance status, illustrating significant
chronic illness and functional impairment. Sputum-
scarce patients had a higher proportion of urine LAM
test positivity as well as a significantly higher mortality
at 8 weeks post-hospitalization. We estimate that urine
LAM correctly identified TB disease in nearly 20% of
these patients, in whom a diagnosis of tuberculosis
would otherwise have been potentially impossible with-
out more invasive testing, and many of whom may not
have been empirically treated for TB as inferred from
published post-mortem studies [15, 23–25]. Interest-
ingly, in our study, there was no concordance between
CXR and urine LAM results, highlighting the difficulty
in using CXR alone as a diagnostic modality in HIV-
infected individuals given the wide array of chest
pathology often seen in this patient population.
Our results illustrate the capability of urine LAM as a
point-of-care test to diagnose TB in sputum-scarce pa-
tients. While it is now understood that a very high bur-
den of undiagnosed tuberculosis exists in hospitalized
HIV-infected patients [15], very little is known about
those who are unable to produce a sputum sample, and
as they are generally excluded from clinical studies, data
on this group is limited. Certainly, smear negative TB
patients are known to have significant diagnostic delays
as well as greater morbidity and mortality compared to
smear positive patients, in whom a diagnosis can more
easily be achieved [26–28] and in this population, urine
LAM used in conjunction with sputum smear micros-
copy has demonstrated benefit in diagnosing culture-
confirmed TB [29]. The diagnostic accuracy of urine
LAM is greatest in HIV-infected patients with advanced
immunosuppression, likely representing disseminated
TB and renal involvement of tuberculosis. [30] This
study highlights the value of urine LAM in this popula-
tion who, due to an inability in producing a sputum
specimen, would otherwise remain undiagnosed and as a
consequence, likely have a higher mortality.
In resource-limited settings, many such patients are
started on empiric TB treatment, a strategy that is
supported by the World Health Organization for
resource-constrained areas with a high HIV prevalence.
[31] However, this may unnecessarily expose patients to
a long course of potentially toxic treatment, and al-
though this strategy has recently demonstrated a poten-
tial survival benefit [32], it preceded the widespread
availability of other diagnostic tools such as Xpert MTB/
RIF testing. Even worse, patients often do not receive
empiric treatment, evidenced by post-mortem studies
demonstrating that up to 50% of patients with autopsy
evidence of tuberculosis are not on treatment for TB
at the time of death. [23] Our results suggest that
urine LAM testing could add an important tool in
the diagnostic armamentarium permitting diagnosis
and appropriate treatment in hospitalized HIV-
infected patients who are sputum-scarce.
Although sputum could not be obtained in only 7.4%
of the patients randomized in the parent study, this is
likely an underestimate of the problem of sputum
scarcity in HIV-infected patients, since sputum induc-
tion facilities were available at all recruitment sites as
part of the study protocol. A higher proportion of HIV-
infected patients presenting to hospital with symptoms
of tuberculosis are likely to be sputum-scarce [12], and
in most resource-limited settings where induction facil-
ities are unavailable, urine LAM may have broader
Table 2 Diagnostic findings, treatment, and outcomes, stratified by ability to produce a sputum sample
Sputum-scarce
N = 187
Sputum-producing
N = 2341
p-value
Positive urine LAM (%) 25/80a (31%) 250/1173 (21%) 0.038
Sputum culture positive 1691/2306 (27%)
Chest X-ray performed 164/187 (88%) 1286/2341 (55%) <0.001
CXR suggestive of TB 96/164 (59%) 615/1286 (48%) 0.010
Received TB treatment 89/186 (48%) 1157/2340 (49%) 0.68
Death within 8 weeks 60/187 (32%) 560/2341 (24%) 0.013
aA total of 80 patients in the sputum-scarce cohort were randomized to the LAM arm in the parent study and had a urine LAM test performed
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applications. In addition, 12.3% of patients screened for
inclusion into the parent study were too sick to provide
informed consent, and therefore were excluded from
study participation. This group of patients were likely to
have also been too sick to provide sputum samples for
diagnostic testing, and thereby represent an additional
population in whom urine LAM may be most beneficial
in achieving a diagnosis of TB.
To our knowledge, this is the first study to demon-
strate the utility of urine LAM testing in patients with
suspected TB who are unable to provide a sputum sam-
ple for diagnostic testing. The implications of this find-
ing are important – sputum-scarce patients present a
significant challenge to clinicians and TB control pro-
grams alike, and highlight deficiencies in current diag-
nostic algorithms that rely on a patient’s ability to
generate a sputum sample. Urine LAM testing in this
group may facilitate rapid diagnosis of tuberculosis and
enable prompt treatment initiation in this very vulner-
able group of patients. It also has implications for de-
signing diagnostic algorithms when both Xpert MTB/
RIF and urine LAM are available, as is the case in many
TB and HIV endemic countries, and suggests that urine
LAM should be the first port of call in sputum-scarce
patients. Thus, our findings inform clinical practice and
patient management strategies.
This study has some important limitations. The cohort
of patients unable to generate a sputum sample was small,
and a majority of the sputum-scarce patients were dispro-
portionately recruited in selected countries, which could
reflect local problems with sputum collection and induc-
tion facilities. However, patients in the sputum-scarce
cohort had different clinical characteristics compared to
the larger group of patients who were able to provide a
sputum sample, suggesting that this group truly represents
a unique subset of patients. In order to calculate the posi-
tive predictive value of urine LAM in the sputum-scarce
group, we had to make the assumption that the specificity
of the urine LAM test does not differ between patients
who are able and unable to produce sputum.
Conclusions
This study estimates that urine LAM testing has a high
positive predictive value in hospitalized HIV-infected pa-
tients who are unable to generate sputum, and that urine
LAM may identify patients with TB who would otherwise
be missed and who have a high mortality. This point-of-
care test acts as a powerful tool to aid the diagnosis of TB
in a particularly challenging and vulnerable patient group,
in whom a missed diagnosis has fatal consequences. This
study supports the use of urine LAM testing in sputum-
scarce, hospitalized HIV-infected patients, and should ap-
propriately be incorporated into diagnostic algorithms.
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